Researchers at the Shirley Ryan AbilityLab are recruiting individuals with chronic (1-10 years) and subacute (10-49 days) cervical spinal cord injury (incomplete) to test the safety and efficacy of an experimental drug, NVG-291. NVG-291 is neuroreparative therapeutic injection that has the potential to treat nervous system damage resulting from injury or disease. Previous lab studies have shown promising results, with NVG-291 demonstrating improvements in locomotion and bladder recovery among individuals with spinal cord injuries.
Starting this August, participants will receive a daily injection of either NVG-291 or a placebo drug for 16 weeks and will be assessed for changes in upper and lower limb function. To enroll, participants must be 18-75, have a cervical spinal cord injury (C7 or higher) and minimal hand function with the ability to initiate one step with the use of assistive device or walker. They must also live in Chicago or have the ability to relocate for the 16 weeks of the trial. The Shirley Ryan AbilityLab can provide an ADA hotel room with two beds if needed at a nearby hotel.
To read more about the study, visit SCI Trials Finder, or to enroll, call: +1 (855) 559-6902.
One response to “Clinical Trial for Promising New SCI Treatment”
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
I am from Nigeria and interested in the trial drug
A spinal cord injury victim